Fustibal is a biotechnology startup focused on fostering affordable healthcare through simpler science. Our mission is to develop accessible targeted therapeutics through data-based computational platforms and modular drug design. To evolve the medical industry, our team dissects life science big data through scientific investigation, reverse engineering, data mining, and computational science. We develop targeted nanomedicines by repurposing and improving existing chemical and biological pharmaceuticals for efficacy, safety, and unmet medical needs. Our kinetics-based, proteomic-driven platforms and therapeutics are cancer-focused but have broad medical applications.
Drug Targeting Platform
• Computational models to design lipid- and antibody-based targeted therapeutics
• Rapid development of chemical and biologic products to fight cancer and HIV
• Refine target-specificity and broaden therapeutic use of pharmaceuticals.
Companion Diagnostic Platform
• Next-generation companion diagnostic rare cell technology for biologics
• Instantaneous monitoring of disease progression and therapeutic effect
• Build a translatable diagnostic database for precision medicine.
David Tran, PhD
Throughout his research career in academia and biotechnology startups, David has investigated targeted drug delivery systems for the treatment of cancer and blood disorders with focuses on chemical and biological pharmaceuticals, nanomedicines, gene therapy, RNA interference, and antibodies. He has worked on multiple NIH-funded and FDA-funded projects on innovative drug development and the assessment of bioequivalence of complex medicines. His extensive research experience includes drug development, molecular biology, cell culture, assay development, microscopy, mathematical modeling, drug release kinetics, pharmacokinetics, biodistribution, and preclinical therapeutic studies. David received his doctorate from the University of California San Francisco and Berkeley Joint Graduate Group in Bioengineering with a minor in the Management of Technology from the Haas School of Business and a Bachelor of Science in Bioengineering at Rice University. He has a background in pharmaceutical science, bioengineering, mathematics, computational science, and business.
Lillian Woung, JD
Lillian is an experienced business development and licensing professional in the United States, Europe, and Asia. As a serial entrepreneur, she confounded and serves as a managing member of IP Edge, an intellectual property management cooperative. Through the years, Lillian has represented a broad spectrum of high tech patent portfolios including medical devices, computer hardware-security, wireless communication, GPS, semiconductors, and automobiles. Her prior work experiences include, among others, Morgan Lewis and Accenture. At Accenture, she excelled as a business process analyst and technology consultant. Lillian holds a Juris Doctor at the University of California Los Angeles, a Bachelor of Science in Chemical Engineering at Rice University, and is admitted to practice in California and before the United States Patent and Trademark Office (USPTO). She has a background in business, intellectual property, high tech, information technology, and chemical engineering.
Sophia Leung, MS
Sophia is a passionate scientist with analytical intellectual property knowledge. In industry, she advanced the batch manufacturing and prolonged storage of crop products in parallel to reducing cost. She also has research experience with crop science, natural preservatives, antioxidants, and storage stability testing. Sophia is a former patent examiner for the USPTO. Aided by comprehensive search tools, she reviewed patent applications and determined the patentability of inventions. Sophia completed her Master of Science in Food Science at the University of Illinois at Urbana-Champaign and a Bachelor of Science in Chemical Engineering at Rice University. She has a background in chemistry, chemical engineering, food science, manufacturing, processing, quality control, and intellectual property.
Fustibal is an affiliate of the California Institute for Quantitative Biosciences (QB3), a nonprofit research and technology commercialization institute spanning the University of California San Francisco (UCSF), Berkeley, and Santa Cruz. Our technical team has access to research core facilities in genomics, proteomics, imaging, structure determination, high-throughput screening, informatics, bioengineering, cell culture, preclinical therapeutics, and more.